Histone Deacetylase Inhibitors for Cancer Therapy: An Evolutionarily Ancient Resistance Response May Explain Their Limited Success

BioEssays - United States
doi 10.1002/bies.201600070
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Histone Deacetylase Inhibitors in Cancer Therapy

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Histone Deacetylase Inhibitors as Cancer Therapeutics

Annals of Translational Medicine
Medicine
2016English

Histone Deacetylase Inhibitors as Therapeutic Agents for Cancer Therapy: Drug Metabolism and Pharmacokinetic Properties

2011English

Inhibitors of Histone-Deacetylase

Journal of Applied Biomedicine
GeneticsMolecular BiologyPharmacologyBiochemistryBiological SciencesToxicologyMedicineAgriculturalNeurosciencePharmaceutics
2005English

Thioredoxin in Cancer—Role of Histone Deacetylase Inhibitors

Seminars in Cancer Biology
Cancer Research
2006English

Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells

Cancers
Cancer ResearchOncology
2019English

Analysis of the Genomic Response of Human Prostate Cancer Cells to Histone Deacetylase Inhibitors

Epigenetics
Cancer ResearchMedicineMolecular Biology
2013English

Pharmacogenomics and Histone Deacetylase Inhibitors

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2016English

Histone Deacetylase Inhibitors: Clinical Implications for Hematological Malignancies

Clinical Epigenetics
GeneticsDevelopmental BiologyMolecular Biology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy